“…Worthy of mention is that several anticancer drugs of marine origin are in clinical use with sufficient approvals, including cytarabine, vidarabine, nelarabine, fludarabine phosphate, trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumabvedotin, enfortumabvedotin, belantamabmafodotin, plitidepsin, lurbinectedin, bryostatins, discodermolide, eleutherobin, and sarcodictyin [41,58]. such as Lactobacilli and Bifidobacteria, modify the mucosa by increasing the production of chemokines and host defense peptides, inducing dendritic cell maturation, and increasing cell proliferation and apoptosis [51]. Marine probiotics can modulate cancer by inducing apoptosis, inhibiting mutagenic activity, downregulating oncogene expression, inducing autophagy, inhibiting kinases, reactivating tumor suppressors, preventing metastasis, and producing meta-biotics, as already shown in B. animalis, B. infantis, B. bifidum, L. paracasei, L. acidophilus, and L. plantarum I-UL4 against MFC7 cancer cells [53,54].…”